# Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee

> **NCT02003365** · PHASE2 · COMPLETED · sponsor: **Pacira Pharmaceuticals, Inc** · enrollment: 50 (actual)

## Conditions studied

- Osteoarthritis of the Knee

## Interventions

- **DRUG:** FX006 10 mg
- **DRUG:** FX006 40 mg
- **DRUG:** TCA IR 40 mg

## Key facts

- **NCT ID:** NCT02003365
- **Lead sponsor:** Pacira Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2024-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02003365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02003365, "Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02003365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*